192 related articles for article (PubMed ID: 25996477)
21. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
[TBL] [Abstract][Full Text] [Related]
22. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
23. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
[No Abstract] [Full Text] [Related]
24. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
25. Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector.
Yang ZZ; Chen XH; Wang D
Clin Lymphoma Myeloma; 2007 Jan; 7(4):296-304. PubMed ID: 17324338
[TBL] [Abstract][Full Text] [Related]
26. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
27. RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells.
King HO; Brend T; Payne HL; Wright A; Ward TA; Patel K; Egnuni T; Stead LF; Patel A; Wurdak H; Short SC
Stem Cell Reports; 2017 Jan; 8(1):125-139. PubMed ID: 28076755
[TBL] [Abstract][Full Text] [Related]
28. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
29. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
30. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
31. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
33. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
34. Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination.
Zhao Q; Guan J; Qin Y; Ren P; Zhang Z; Lv J; Sun S; Zhang C; Mao W
Biomed Pharmacother; 2018 Jan; 97():115-119. PubMed ID: 29080451
[TBL] [Abstract][Full Text] [Related]
35. Identification of MicroRNAs With
Weidle UH; Nopora A
Cancer Genomics Proteomics; 2020; 17(4):321-334. PubMed ID: 32576578
[TBL] [Abstract][Full Text] [Related]
36. Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Ward A; Dong L; Harris JM; Khanna KK; Al-Ejeh F; Fairlie DP; Wiegmans AP; Liu L
Bioorg Med Chem Lett; 2017 Jul; 27(14):3096-3100. PubMed ID: 28545975
[TBL] [Abstract][Full Text] [Related]
37. A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.
Alagpulinsa DA; Ayyadevara S; Shmookler Reis RJ
Front Oncol; 2014; 4():289. PubMed ID: 25401086
[TBL] [Abstract][Full Text] [Related]
38. Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair.
Sonoda E; Zhao GY; Kohzaki M; Dhar PK; Kikuchi K; Redon C; Pilch DR; Bonner WM; Nakano A; Watanabe M; Nakayama T; Takeda S; Takami Y
DNA Repair (Amst); 2007 Mar; 6(3):280-92. PubMed ID: 17123873
[TBL] [Abstract][Full Text] [Related]
39. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Jacquemont C; Taniguchi T
Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
[TBL] [Abstract][Full Text] [Related]
40. Targeting RAD51 enhances chemosensitivity of adult T‑cell leukemia‑lymphoma cells by reducing DNA double‑strand break repair.
Yang M; Tian X; Fan Z; Yu W; Li Z; Zhou J; Zhang W; Liang A
Oncol Rep; 2019 Dec; 42(6):2426-2434. PubMed ID: 31638261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
